Dosage Forms

FDA has granted an expanded Emergency Use Authorization to Pfizer and BioNTech’s COVID-19 vaccine boosters in individuals aged 50 years and older.

Lonza has joined IPAC-RS, providing benefits to Lonza’s inhalation- related businesses due to IPAC-RS’ global voice of the orally inhaled and nasal drug products industry.

The author introduces a practical approach to determining the best estimate of probability for passing multiple stage dissolution tests.

Collaboration and new tools aid efforts to implement new processing technologies for small-molecule drug product manufacturing.

The continuous, aseptic fill/finish process is finding use in vaccines and biologic drugs.

Innovations address supply-chain constraints, serialization, and new requirements for sustainable and patient-centric designs.

Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.

Innovations address sustainable and patient-centric designs.

Technological advances are helping shape the dosage forms of the future.

Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.

Process performance metrics of eight different mechanical devices were assessed to evaluate compliance with regulatory and compendial criteria.

Smart manufacturing transforms management of tablet and capsule equipment and processes.

Biocon Biologics will acquire Viatris’ global biosimilars business, including the company’s portfolio of in-licensed biosimilar assets, in a transaction valued at over $3.3 billion.

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program.

TFF Pharmaceuticals announces findings that inhaled niclosamide significantly inhibits viral replication of the Omicron variant of SARS-CoV-2.

In this episode of the Drug Solutions Podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview Sean Tucker, PhD, chief scientific officer of Vaxart, on developing oral recombinant vaccines.

PharmTech interviewed Sartorius about SUS innovations and trends.

Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.

Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

CDMOs offer expertise and capacity for spray drying.

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.

In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.

Protective external packaging ensures COVID-19 vaccines arrive safely.

The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.

Intravacc is partnering with Leiden University Medical Center for the development and evaluation of a new intranasal coronavirus vaccine candidate in a clinical Phase I/II study.

Workforce training is crucial for biopharmaceutical manufacturing.

Guide addresses challenges of applying GMPs to autologous cell therapy manufacturing.

Fujifilm’s center adds local support in Suzhou, China for cell culture media optimization.